Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Quest's C. difficile Molecular Test

NEW YORK (GenomeWeb News) – Quest Diagnostics said today that the US Food and Drug Administration has given 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler.

The test is from Quest's wholly owned business Focus Diagnostics and is for aiding in the diagnosis of C. difficile. Simplexa tests use real-time PCR to qualitatively detect viruses, bacteria, and other analytes, and the C. difficile test uses a proprietary chemistry to eliminate nucleic acid sample extraction, allowing hospitals and other laboratories to achieve test results in about one hour, Quest said.

The test is performed on liquid or unformed human stool samples to detect the toxin B (tcdB) gene of C. difficile, including NAP1. Focus launched the test in Europe during the second quarter of 2011.

In the US about 14,000 people die each year from C. difficile-associated diseases, Quest said, citing statistics from the US Centers for Disease Control and Prevention.

"Fast, reliable PCR tests that are highly specific and sensitive in the detection of the tcdB gene … are essential for identifying and treating this infection as well as containing its spread," Jay Lieberman, medical director of infectious disease for Quest and Focus, said in a statement.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.